Advertisement
BIIB or MYGN or WINT
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s), and WINT’s FA Score reflects 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- MYGN’s FA Score: 1 green, 4 red.
- WINT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s), and WINT’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 3 bearish.
- MYGN’s TA Score: 4 bullish, 4 bearish.
- WINT’s TA Score: 4 bullish, 3 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -1.86% price change this week, while MYGN (@Medical Specialties) price change was -1.18% , and WINT (@Biotechnology) price fluctuated +4.21% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +10.48%, and the average quarterly price growth was +8.86%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.80%. For the same industry, the average monthly price growth was +3.14%, and the average quarterly price growth was +0.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
MYGN is expected to report earnings on Jul 31, 2025.
WINT is expected to report earnings on Apr 15, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Specialties (-1.80% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Biotechnology (-0.75% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | MYGN | WINT | |
| Capitalization | 31.3B | 1.93B | 2.17M |
| EBITDA | 2.04B | -197.4M | -9.36M |
| Gain YTD | -14.563 | -63.311 | -96.610 |
| P/E Ratio | 26.95 | N/A | 0.83 |
| Revenue | 9.84B | 753M | 0 |
| Total Cash | 1.05B | 141M | 917K |
| Total Debt | 7.34B | 152M | 2.01M |
BIIB | MYGN | WINT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 23 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 97 Overvalued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 71 | 91 | 97 | |
PRICE GROWTH RATING 1..100 | 61 | 65 | 97 | |
P/E GROWTH RATING 1..100 | 96 | 2 | 5 | |
SEASONALITY SCORE 1..100 | n/a | 8 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WINT's Valuation (57) in the Biotechnology industry is in the same range as BIIB (87) and is somewhat better than the same rating for MYGN (97). This means that WINT's stock grew similarly to BIIB’s and somewhat faster than MYGN’s over the last 12 months.
WINT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100) and is in the same range as MYGN (100). This means that WINT's stock grew similarly to BIIB’s and similarly to MYGN’s over the last 12 months.
BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as MYGN (91) and is in the same range as WINT (97). This means that BIIB's stock grew similarly to MYGN’s and similarly to WINT’s over the last 12 months.
BIIB's Price Growth Rating (61) in the Biotechnology industry is in the same range as MYGN (65) and is somewhat better than the same rating for WINT (97). This means that BIIB's stock grew similarly to MYGN’s and somewhat faster than WINT’s over the last 12 months.
MYGN's P/E Growth Rating (2) in the Biotechnology industry is in the same range as WINT (5) and is significantly better than the same rating for BIIB (96). This means that MYGN's stock grew similarly to WINT’s and significantly faster than BIIB’s over the last 12 months.
| BIIB | MYGN | WINT | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 71% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 81% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 76% | 1 day ago 90% |
| MACD ODDS (%) | N/A | 1 day ago 82% | N/A |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 83% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 75% | 1 day ago 90% |
| Advances ODDS (%) | 5 days ago 54% | 5 days ago 73% | 18 days ago 76% |
| Declines ODDS (%) | 1 day ago 70% | 24 days ago 82% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 74% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 81% | 1 day ago 90% |
Advertisement
MYGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.
| Ticker / NAME | Correlation To MYGN | 1D Price Change % | ||
|---|---|---|---|---|
| MYGN | 100% | -3.08% | ||
| WAT - MYGN | 39% Loosely correlated | -2.08% | ||
| ATEC - MYGN | 34% Loosely correlated | -2.73% | ||
| VCYT - MYGN | 32% Poorly correlated | -0.94% | ||
| AORT - MYGN | 31% Poorly correlated | -1.70% | ||
| IQV - MYGN | 31% Poorly correlated | -1.41% | ||
More | ||||
WINT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WINT has been loosely correlated with MLEC. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if WINT jumps, then MLEC could also see price increases.
| Ticker / NAME | Correlation To WINT | 1D Price Change % | ||
|---|---|---|---|---|
| WINT | 100% | -1.99% | ||
| MLEC - WINT | 49% Loosely correlated | N/A | ||
| DVHGF - WINT | 37% Loosely correlated | N/A | ||
| INMB - WINT | 31% Poorly correlated | -2.78% | ||
| DYN - WINT | 29% Poorly correlated | -0.35% | ||
| CDTX - WINT | 27% Poorly correlated | -5.85% | ||
More | ||||